


MODERN PHARMACEUTICS

SECOND EDITION, REVISED AND EXPANDED

EDITED BY

GILBERT S. BANKER

CHRISTOPHER T. RHODES



Library of Congress Cataloging-in-Publication Data

Modern pharmaceuticals.

(Drugs and the pharmaceutical sciences ; v. 40)

Includes bibliographical references.

1. Drugs--Dosage forms. 2. Biopharmaceutics.
3. Pharmacokinetics. 4. Pharmaceutical industry--Quality
control. I. Banker, Gilbert S. II. Rhodes,
Christopher T. III. Series.

RS200.M63 1989

615'.1

89-23365

ISBN 0-8247-7499-X

COPYRIGHT © 1990 by MARCEL DEKKER, INC. ALL RIGHTS RESERVED

Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval system, without permission in writing from the publisher.

MARCEL DEKKER, INC.

270 Madison Avenue, New York, New York 10016

PRINTED IN THE UNITED STATES OF AMERICA

IV. SUSPENSIONS

A. Advantages and Disadvantages of Suspension as a Dosage Form

Even those of use who have invested considerable time and labor in the formulation of suspensions must admit that the suspension has a number of disadvantages as a dosage form. First, uniformity and accuracy of dose, even when the preparation is nurse administered, is unlikely to compare favorably with that obtainable by the use of tablets or capsules. Sedimentation and compaction of sediment cause problems which are by no means always easy to solve. Further, the product is liquid and relatively bulky; these properties are disadvantageous to both pharmacist and patient. Formulation of an effective and pharmaceutically elegant suspension is usually much harder to achieve than of a tablet or capsule of the same drug. However, suspensions do have some advantages which can, under certain circumstances, outweigh their disadvantages.

Many of the more recently developed drugs are basically hydrophobic in nature and thus their aqueous solubilities are low. Thus solutions of these drugs, containing an appropriate dosage, would be of an unacceptably large volume. Suspensions allow the development of a liquid dosage form containing an appropriate quantity of drug in a reasonably small volume. Further, resistance to hydrolysis and oxidation is generally good compared with that observed in aqueous solution. Suspensions can also be used to mask the taste of drugs. Also, there is a significant proportion of the population, especially very young children, who have difficulty in swallowing tablets or capsules. In recent years increasing attention has been given to the use of suspensions in intramuscular injection for depot therapy. For example, a number of research teams are presently developing intramuscular suspensions of contraceptive steroids that may give contraceptive protection for periods in excess of a year.

B. Physical Stability of Suspensions

Pharmaceutical suspensions are basically unstable systems. Aggregation of suspended particles and sedimentation (and possibly impaction of sediment) present real problems to the pharmaceutical formulator. As has already been indicated, much of the theory relevant to the formulation of acceptable pharmaceutical suspensions is derived from the findings of colloid scientists who have studied model systems. There are, however, several important differences between model colloidal systems and pharmaceutical suspensions, some of the more important of which are shown in Table 6.

Repulsive and Attractive Forces Between Particles

Much of the present-day theory regarding the charge on suspended particles results from the work of four scientists: Derjaguin and Landau from the Soviet Union, and Verney and Overbeek from the Netherlands. The theory is thus often referred to as the DLVO theory. This theory allows us to develop insight into the factors responsible for controlling the rate at which particles in a suspension will come together, or aggregate, to form duplets (two particles), triplets (three particles), and so on. The process of aggregation will accelerate sedimentation and affect redispersibility and thus is important to the pharmaceutical scientist formulating a suspension. The total energy of interaction, V_T , between two particles is defined as

Table 6. Differences Between Colloidal and Pharmaceutical Suspensions

Model colloidal suspensions	Pharmaceutical suspensions
Homodisperse (i.e., suspended particles almost all the same size)	Heterodisperse (i.e., suspended particles of a considerable range of sizes)
Particles less than about 1 μm in diameter	Particles often very much larger than 1 μm
Continuous phase simple in nature; basically aqueous	Continuous, often complex: containing many substances as well as water
Shapes of particles usually close to spherical	Shapes often quite nonspherical (e.g., needle crystals)
Solids content usually low (e.g., 2%)	Solids content sometimes very high (e.g., 50%)

$$V_T = V_R + V_A \quad (5)$$

where V_R and V_A represent the repulsive and attractive forces, respectively. (It is possible to estimate V_R and V_A ; see Matthews and Rhodes [23]). Figure 2 exemplifies some energy-of-interaction curves. Curve A applies when $V_R > V_A$, that is, the term V_T is always positive because of the high potential at the double layer. In such cases a suspension would exhibit very good resistance to aggregation (i.e., flocculation or coagulation) provided that the particles are not sufficiently large to sediment under gravity.

Curve B shows a high potential energy barrier, V_M , which must be surmounted if the particles are to approach one another sufficiently closely to enter the deep primary energy minimum at P. If the height of the energy barrier V_M greatly exceeds the mean thermal energy of the particles, they will not be able to enter P. The value V_M required to just prevent this is probably equivalent to a zeta potential of about 50 mV. Thus, in formulating a pharmaceutical suspension it is often useful to aim at a system with a zeta potential of more than 50 mV. Aggregates that do form at P are likely to be very tightly bound together since H, the interparticulate distance, is small and the energy well at P is often quite deep. Thus in a pharmaceutical preparation very vigorous shaking would be required to redisperse the product. It should also be noted that there is a secondary energy minimum at S. If this trough is sufficiently deep, loose aggregates can form at this point; these will usually be easy to redisperse.

Curve C shows the situation that exists when attractive forces completely overwhelm repulsive forces (i.e., $V_A > V_R$). Under other such conditions very rapid aggregation will occur.

The curve V_S shows the stabilizing effect of surfactants adsorbed on the surface of suspended particles; it shows a quite sharp cutoff point at $2d$, where d is the thickness of the adsorbed surfactant layer. The strongly hydrated nature of surfactant head groups impedes particle-particle




Figure 2 Total energy of interaction curve between suspended particles (h is the interparticulate distance).

contact, which would result in aggregation. Thus, even nonionic surfactants can be used to stabilize suspensions. It should be noted, however, that an excessive quantity of surfactant can, in some systems, have a significantly adverse affect on stability.

Aggregation Kinetics

The aggregation of particles in a suspension can be termed flocculation or coagulation. The term coagulation should be used when the forces involved are primarily physical due to reduction in the repulsive forces at the double layer. The term flocculation is applied to those cases in which "bridging" occurs between particles. However, since in many pharmaceutical systems the exact nature of the forces is somewhat obscure, we shall restrict ourselves here to use of the term aggregation. Using simple diffusion theory [24], Von Smoluchowski derived equations for both rapid aggregation (when all particle-particle collisions result in aggregation) and slow aggregation (in which only a fraction, α , of all particle-particle collisions result in the formation of aggregates). Pharmaceutical scientists are concerned primarily with slow aggregation, since the aggregation in suspensions of drugs is mainly slow. The $t_{1/2}$, time for the initial number of particles (singlets) in a suspension to decrease by 50%, because of aggregation is given by

$$t_{1/2} = \frac{1}{4D_1RN_0\alpha} \quad (6)$$

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.